Evidence map›Paper›PMID 39792785›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Novel Leech Antimicrobial Peptides, Hirunipins: Real-Time 3D Monitoring of Antimicrobial and Antibiofilm Mechanisms Using Optical Diffraction Tomography.

S Dinesh Kumar, Jeongwon Park, Naveen Kumar Radhakrishnan, Yam Prasad Aryal, Geon-Hwi Jeong, In-Hyeok Pyo, Byambasuren Ganbaatar, Chul Won Lee, Sungtae Yang, Younhee Shin and 6 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Therapeutic Bioactivity Exerted by theMolecules (Basel, Switzerland) · 2025
    Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

S Dinesh KumarDepartment of Cellular & Molecular Medicine, School of Medicine, Chosun University, Gwangju, 61452, Republic of Korea.
Jeongwon ParkGwangju Center, Korea Basic Science Institute (KBSI), Gwangju, 61751, Republic of Korea.
Naveen Kumar RadhakrishnanDepartment of Biomedical Sciences, Graduate School, Chosun University, Gwangju, 61452, Republic of Korea.
Yam Prasad AryalDepartment of Biological Sciences and Biotechnology, College of Natural Sciences, Chungbuk National University, Cheongju, Chungbuk, 28644, Republic of Korea.
Geon-Hwi JeongDepartment of Biological Sciences and Biotechnology, College of Natural Sciences, Chungbuk National University, Cheongju, Chungbuk, 28644, Republic of Korea.
In-Hyeok PyoDepartment of Biological Sciences and Biotechnology, College of Natural Sciences, Chungbuk National University, Cheongju, Chungbuk, 28644, Republic of Korea.
Byambasuren GanbaatarDepartment of Chemistry, Chonnam National University, Gwangju, 61186, Republic of Korea.
Chul Won LeeDepartment of Chemistry, Chonnam National University, Gwangju, 61186, Republic of Korea.
Sungtae YangInstitute of Well-Aging Medicare & CSU G-LAMP Project Group, Chosun University, Gwangju, 61452, Republic of Korea.
Younhee ShinResearch and Development Center, Insilicogen Inc, Yongin-si, Gyeonggi-do, 16954, Republic of Korea.
Sathiyamoorthy SubramaniyamResearch and Development Center, Insilicogen Inc, Yongin-si, Gyeonggi-do, 16954, Republic of Korea.
Yu-Jin LimResearch and Development Center, Insilicogen Inc, Yongin-si, Gyeonggi-do, 16954, Republic of Korea.
Sung-Hak KimDepartment of Animal Science, Chonnam National University, Gwangju, 61186, South Korea.
Seongsoo LeeGwangju Center, Korea Basic Science Institute (KBSI), Gwangju, 61751, Republic of Korea.
Song Yub ShinDepartment of Cellular & Molecular Medicine, School of Medicine, Chosun University, Gwangju, 61452, Republic of Korea.
Sung-Jin ChoDepartment of Biological Sciences and Biotechnology, College of Natural Sciences, Chungbuk National University, Cheongju, Chungbuk, 28644, Republic of Korea.ORCID https://orcid.org/0000-0001-6126-6310

Funding

ABC-based Regenerative BioTherapeutics (ABC project) grant funded by the Korea government (the Ministry of Science and ICT) RS-2024-00426031Commercialization Promotion Agency for R&D Outcomes (COMPA) 2710006249Global-Learning & Academic Research Institution for Master's·PhD students, and Postdocs (LAMP) Program of the NRF grant funded by the Ministry of Education RS-2023-00285353Korea Basic Science Institute A423320Ministry of Education 2020R1A6A1A06046235Ministry of Education 2021R1I1A3050071Ministry of Education 2023R1A2C1007868Ministry of Science and ICT NRF-2022R1A2C1005493Ministry of Science and ICT NRF-2022R1A5A2030454National Institute of Biological Resources (NIBR), funded by the Ministry of Environment (MOE) NIBRE202404National Research Foundation of KoreaRegional Innovation Strategy (RIS) through NRF funded by the Ministry of Education(MOE) 2021RIS-001
6 · The paper itself

Abstract

Antimicrobial peptides (AMPs) are promising agents for treating antibiotic-resistant bacterial infections. Although discovering novel AMPs is crucial for combating multidrug-resistant bacteria and biofilm-related infections, their clinical potential relies on precise, real-time evaluation of efficacy, toxicity, and mechanisms. Optical diffraction tomography (ODT), a label-free imaging technology, enables real-time visualization of bacterial morphological changes, membrane damage, and biofilm formation over time. Here, a computational analysis of the leech transcriptome using an advanced AI-based peptide screening strategy with ODT to identify potential AMPs is employed. Among the 19 potential AMPs identified, hirunipin 2 demonstrates potent antibacterial activity, low mammalian cytotoxicity, and minimal hemolytic effects. It demonstrates efficacy comparable to melittin, resistance to physiological salts and human serum, and a low likelihood of inducing bacterial resistance. Microscopy and 3D-ODT confirm its disruption of bacterial membranes and intracellular aggregation, leading to cell death. Notably, hirunipin 2 effectively inhibits biofilm formation, eradicates preformed biofilms, and synergizes with antibiotics against multidrug-resistant Acinetobacter baumannii (MDRAB) by enhancing membrane permeability. Additionally, hirunipin 2 significantly suppresses pro-inflammatory cytokine expression in LPS-stimulated macrophages, highlighting its anti-inflammatory properties. These findings highlight hirunipin 2 as a strong candidate for developing novel antibacterial, anti-inflammatory, and antibiofilm therapies, particularly against multidrug-resistant bacterial infections.

Indexed as

Anti-Bacterial AgentsAntimicrobial PeptidesBiofilmsLeechesAnimalsComputer SimulationHaCaT CellsHumansMiceMicrobial Sensitivity TestsNIH 3T3 CellsRAW 264.7 CellsTomography, OpticalTranscriptomeAnti-Bacterial AgentsAntimicrobial Peptidesantibiofilmantimicrobial peptideHirunipinLeechODT technology

Identifiers

PMID39792785
PMCPMC11905058

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.